Ricolinostat is not a highly selective HDAC6 inhibitor

被引：7
|
作者：
Medard, Guillaume [1 ]
Sheltzer, Jason M. [2 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Dept Chem, Prote Core Facil, Athens, Greece
[2] Yale Univ, Sch Med, New Haven, CT 06520 USA
来源：
NATURE CANCER | 2023年 / 4卷 / 06期
关键词：
D O I：
10.1038/s43018-023-00582-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：807 / 808
页数：2
相关论文
共 50 条
  • [21] Tau - an inhibitor of deacetylase HDAC6 function
    Perez, Mar
    Santa-Maria, Ismael
    Gomez de Barreda, Elena
    Zhu, Xiongwei
    Cuadros, Raquel
    Roman Cabrero, Jose
    Sanchez-Madrid, Francisco
    Dawson, Hana N.
    Vitek, Michael P.
    Perry, George
    Smith, Mark A.
    Avila, Jesus
    JOURNAL OF NEUROCHEMISTRY, 2009, 109 (06) : 1756 - 1766
  • [22] Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma
    Amengual, Jennifer E.
    Johannet, Paul M.
    Zullo, Kelly
    Lombardo, Maximilian
    O'Connor, Owen A.
    BLOOD, 2014, 124 (21)
  • [23] Endeavors toward a specific inhibitor for HDAC6
    Kato, Tamaki
    Jose, Binoy
    Okamura, Shinji
    Sumida, Yuko
    Yoshida, Minoru
    Nishino, Norikazu
    PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS & THERAPEUTICS, 2004, : 524 - 525
  • [24] Inhibitors selective for HDAC6 in enzymes and cells
    Gupta, Praveer K.
    Reid, Robert C.
    Liu, Ligong
    Lucke, Andrew J.
    Broomfield, Steve A.
    Andrews, Melanie R.
    Sweet, Matthew J.
    Fairlie, David P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (23) : 7067 - 7070
  • [25] Structure, Functions and Selective Inhibitors of HDAC6
    Liang, Tao
    Fang, Hao
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (28) : 2429 - 2447
  • [26] Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
    Lee, Elizabeth K.
    Tan-Wasielewski, Zhenying
    Matulonis, Ursula A.
    Birrer, Michael J.
    Wright, Alexi A.
    Horowitz, Neil
    Konstantinopoulos, Panagiotis A.
    Curtis, Jennifer
    Liu, Joyce F.
    GYNECOLOGIC ONCOLOGY REPORTS, 2019, 29 : 118 - 122
  • [27] Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma
    Yee, Andrew J.
    Voorhees, Peter M.
    Bensinger, William
    Berdeja, Jesus G.
    Supko, Jeffrey G.
    Richardson, Paul G.
    Tamang, David
    Jones, Simon S.
    Patrick, Gretchen
    Wheeler, Catherine
    Raje, Noopur
    BLOOD, 2014, 124 (21)
  • [28] Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations
    Amengual, Jennifer E.
    Lombardo, Maximilian
    Zullo, Kelly M.
    Johannet, Paul M.
    Prabhu, Sathyen A.
    Yulissa, Gonzalez
    Scotto, Luigi
    Wei, Ying
    Duong, Jimmy
    O'Connor, Owen A.
    BLOOD, 2015, 126 (23)
  • [29] Alternative HDAC3 and HDAC6 deacylase activities and the structural activity relationship of a selective HDAC3 inhibitor
    Zhang, Cheng
    Inks, Elizabeth
    McClure, Jesse
    Chou, C. James
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [30] DISCOVERY OF A NEW HDAC6 INHIBITOR FOR THE TREATMENT OF GLIOBLASTOMA
    Auzmendi-Iriarte, J.
    Saenz-Antonanzas, A.
    Andermatten, J.
    Elua-Pinin, A.
    Aldaba, E.
    Vara, Y.
    Matheu, A.
    NEURO-ONCOLOGY, 2019, 21 : 53 - 54
12345